56% ORR in TKI-naïve patients, including 86% ORR by PPR criteria and 100% ORR in APEX patients treated at 100 mg BID with exposures consistent with go-forward dose Nearly all patients achieved at.
56% ORR in TKI-naïve patients, including 86% ORR by PPR criteria and 100% ORR in APEX patients treated at 100 mg BID with exposures consistent with go-forward dose
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
New Dupixent® (dupilumab) Data Showcasing Improvements Across Four Type 2 Inflammatory Diseases to be Presented at 2021 AAAAI Annual Meeting
News provided by
Share this article
TARRYTOWN, N.Y. and PARIS, Feb. 1, 2021 /PRNewswire/
Improvements were noted across key disease measures in certain patients with asthma, atopic dermatitis, eosinophilic esophagitis and chronic rhinosinusitis with nasal polyposis
New analyses build on a robust body of evidence reinforcing the role of Dupixent in certain diseases driven by type 2 inflammation
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced new data further examining Dupixent
® (dupilumab) in diseases driven by type 2 inflammation including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP) and eosinophilic esophagitis. These data will be presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) Virtual Annual Meeting, taking place from February 26 to March 1.